Cue Biopharma, Inc. 2017 Annual Report (10-K) Summary
Business Context and Reporting Period
Cue Biopharma, Inc. is a preclinical-stage biopharmaceutical company developing a proprietary class of biologic drugs (CUE Biologics) designed to selectively modulate the human immune system for the treatment of cancers and autoimmune disorders. The company completed its initial public offering (IPO) on December 27, 2017. This report covers the fiscal year ended December 31, 2017. The company has no approved products and has not generated any revenue to date.
Key Financial Metrics
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Total Operating Expenses | $23,233,870 | $7,658,335 |
| Net Loss | $(23,233,835) | $(7,658,283) |
| Cash and Cash Equivalents (Year End) | $63,533,649 | $14,925,820 |
| Working Capital | $59,718,357 | $14,070,638 |
| Accumulated Deficit | $(32,820,848) | $(9,587,013) |
Debt and Liquidity: The company has no long-term debt. Liquidity is supported by cash proceeds from the IPO ($61.9 million net) and a $2.5 million upfront payment from a collaboration agreement with Merck. Management believes existing cash resources are sufficient to fund operations for at least 12 months.
Material Changes vs. Prior Period
- Revenue: Remained at $0 as the company is preclinical with no commercial products.
- Operating Expenses: Increased by approximately $15.6 million (203%) from 2016 to 2017. This was driven by a $13.2 million increase in Research and Development (R&D) expenses and a $2.4 million increase in General and Administrative (G&A) expenses.
- R&D Drivers: Significant increases were due to licensing fees (including a $5.0 million non-cash charge for stock issued to Albert Einstein College of Medicine), expanded research activities, and costs related to the lead candidate CUE-101.
- Financing Activities: Net cash provided by financing activities surged to $62.0 million in 2017, primarily due to the IPO, compared to $15.0 million in 2016 from private placements.
Guidance, Outlook, and Risks
Outlook and Strategy: The company intends to file an Investigational New Drug (IND) application for its lead candidate, CUE-101 (targeting HPV-related cancers), in the first quarter of 2019, pending preclinical data. The company plans to continue expanding its pipeline in oncology and autoimmune diseases.
Collaboration: In November 2017, Cue entered a collaboration with Merck Sharp & Dohme Corp. to research and develop biologics for autoimmune diseases. Cue received a $2.5 million upfront payment and is eligible for up to $371 million in potential milestone payments and tiered royalties.
Risks and Contingencies:
- Preclinical Stage: No products have been tested in humans; clinical trials may fail or reveal toxicities.
- Capital Needs: The company expects to incur significant losses for the foreseeable future and will require additional financing to continue operations.
- Regulatory: Success depends on obtaining FDA approvals, which are uncertain and costly.
- Intellectual Property: Reliance on licensed technology from Albert Einstein College of Medicine; failure to meet diligence milestones could result in license termination.
Key Facts for Investor Verification
- Cash Runway: Verify if the $63.5 million cash balance is sufficient to fund the planned IND filing for CUE-101 and ongoing R&D through 2019 without immediate dilution.
- Merck Collaboration Terms: Review the specific milestones required to unlock the potential $371 million in future payments and the exclusivity restrictions on autoimmune development.
- Einstein License Obligations: Confirm compliance with diligence milestones and royalty obligations under the license with Albert Einstein College of Medicine.
- CUE-101 Preclinical Data: Assess the robustness of the ex vivo human data and animal model results supporting the planned Q1 2019 IND filing.
- Stock-Based Compensation: Monitor the impact of the $2.8 million stock-based compensation expense in 2017 and future vesting schedules on cash burn.